Loss of heterozygosity: a potential tool in management of oral premalignant lesions?
Loss of heterozygosity: a potential tool in management of oral premalignant lesions?
复制标题
DOI：
10.1034/j.1600-0714.2001.300901.x
复制
发表时间：
2001-10
期刊：
影响因子：
--
通讯作者：
Lewei Zhang;M. Rosin;M. Rosin
中科院分区：
文献类型：
--
作者：
Lewei Zhang;M. Rosin;M. Rosin
口腔白斑是一组不同种类的病变，表现出不同程度的癌症进展风险。组织学(异型增生的存在和程度)是目前评估这种风险的金标准，在判断高级别侵袭前病变的恶性风险方面是相当有效的。然而，对于没有不典型增生或有轻微不典型增生的病变来说，它是一个很差的预测指标，因为这些病变中只有几个会进展为癌症。这给临床医生带来了一个巨大的两难境地，即这些病变是否应该进行积极的治疗。最近的研究表明，含有已知或推测的抑癌基因的特定染色体区域的丢失(杂合性缺失，LOH)是口腔癌前病变后续进展的早期预测因素。将LOH结果结合到口腔癌前病变的分期中可以提高我们识别和处理高危癌前病变的能力，特别是那些组织学相对良性但高危基因变化(高危LOH模式)的病变。
Oral leukoplakia, a heterogeneous group of lesions, demonstrates a varying degree of risk for cancer progression. Histology (presence and degree of dysplasia), the current gold standard for assessing this risk, is reasonably effective in judging the malignant risk of high-grade pre-invasive lesions. It is, however, a poor predictor for lesions without dysplasia, or with minimal dysplasia, as only a few of these lesions will progress to cancer. This poses an enormous dilemma for clinicians as to whether these lesions should be aggressively treated or not. Recent studies show that loss of specific chromosomal regions (loss of heterozygosity, LOH) that contain known or presumptive tumor suppressor genes is an early predictor of subsequent progression of oral premalignant lesions. Incorporation of LOH findings into staging of oral premalignancy could improve our ability to identify and manage high-risk premalignant lesions, particularly those with relatively benign histology but high-risk genetic changes (high-risk LOH pattern).